بدائل البحث:
ng decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
nm decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
n decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), _ decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
5 ng » 5 mg (توسيع البحث), 5 g (توسيع البحث), 5 nm (توسيع البحث)
4 nm » 4 mm (توسيع البحث), 5 nm (توسيع البحث), 1 nm (توسيع البحث)
ng decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
nm decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
n decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), _ decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
5 ng » 5 mg (توسيع البحث), 5 g (توسيع البحث), 5 nm (توسيع البحث)
4 nm » 4 mm (توسيع البحث), 5 nm (توسيع البحث), 1 nm (توسيع البحث)
-
61
-
62
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
63
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
64
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
65
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
66
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
67
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
منشور في 2022"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"
-
68
The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties.
منشور في 2020"…<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <i>Xenopus</i> oocytes. …"
-
69
-
70
-
71
-
72
-
73
-
74
Diabetic kidney shows decreased klotho expression.
منشور في 2021"…<p>(a) Representative images of the kidney from normal and diabetic biopsies showing the decreased klotho expression in diabetic podocytes by IHC. …"
-
75
-
76
-
77
-
78
-
79
-
80